{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:07:03Z","timestamp":1789135623365,"version":"build-2803163510"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Most risk-based breast cancer prevention and screening strategies rely on estimated invasive breast cancer risk. A recently developed model from the Breast Cancer Surveillance Consortium (BCSC) identifies women at elevated advanced cancer risk (prognostic pathologic stage II or greater) despite undergoing regular mammography screening.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To describe the characteristics of women identified for risk-based interventions based on advanced versus invasive breast cancer risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Cross-sectional study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Women aged 40\u201374\u00a0years undergoing mammography screening in routine clinical practice at 165 radiology facilities participating in the BCSC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Measures<\/jats:title>\n                    <jats:p>Established BCSC risk models were used to calculate cumulative 6-year advanced breast cancer risk and BCSC 5-year invasive breast cancer risk, stratified by age, race and ethnicity, breast density, and body mass index.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Results<\/jats:title>\n                    <jats:p>Among 756,971 included women, the Spearman correlation between advanced and invasive cancer risk scores was 0.75. 31.9% of women had intermediate\/high (\u2265\u20090.38%) advanced cancer risk and 32.5% had intermediate\/high (\u2265\u20091.67%) invasive cancer risk. 21.1% had intermediate\/high risk in both models and 22.1% had intermediate\/high risk in only one model. Thirty-five percent of women with intermediate\/high invasive cancer risk had low\/average advanced cancer risk, and 16% of women with low\/average invasive cancer risk had intermediate\/high advanced cancer risk. Among women with intermediate\/high advanced cancer risk, 17.5% were age 40\u201349, 25.7% were Black, 69.7% had dense breasts, and 81.1% were overweight\/obese. Among women with intermediate\/high invasive breast cancer risk, 5.2% were age 40\u201349, 11.9% were Black, 56.5% had dense breasts, and 70.6% were overweight\/obese.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There are substantial differences in the characteristics of women identified as having elevated risk based on the advanced versus invasive breast cancer risk models. The advanced cancer risk model is important for identifying women who are young, Black, overweight\/obese, or have dense breasts at intermediate\/higher advanced cancer risk for consideration of risk-based interventions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11606-026-10237-5","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T22:57:42Z","timestamp":1771455462000},"page":"3329-3338","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Advanced Versus Invasive Breast Cancer Risk in a Screening Population: Implications for Risk-based Prevention and Screening Strategies"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7948-8317","authenticated-orcid":false,"given":"Brian L.","family":"Sprague","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte C.","family":"Gard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Tice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna N. A.","family":"Tosteson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph I.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana L.","family":"Miglioretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla","family":"Kerlikowske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"10237_CR1","doi-asserted-by":"publisher","unstructured":"Shieh Y, Eklund M, Madlensky L, et al. Breast cancer screening in the precision medicine Era: risk-based screening in a population-based Trial. J Natl Cancer Inst. 2017;109(5). https:\/\/doi.org\/10.1093\/jnci\/djw290.","DOI":"10.1093\/jnci\/djw290"},{"key":"10237_CR2","doi-asserted-by":"publisher","unstructured":"Yala A, Mikhael PG, Lehman C.  Optimizing risk-based breast cancer screening policies with reinforcement learning. Nat Med. 2022;28(1):136-143.  https:\/\/doi.org\/10.1038\/s41591-021-01599-w.","DOI":"10.1038\/s41591-021-01599-w"},{"key":"10237_CR3","doi-asserted-by":"publisher","unstructured":"Mukama T, Kharazmi E, Xu X.  Risk-Adapted Starting Age of Screening for Relatives of Patients With Breast Cancer. JAMA Oncol. 2020;6(1):68-74.  https:\/\/doi.org\/10.1001\/jamaoncol.2019.3876.","DOI":"10.1001\/jamaoncol.2019.3876"},{"key":"10237_CR4","doi-asserted-by":"publisher","unstructured":"Moorthie S, Babb de Villiers C, Burton H, et al. Towards implementation of comprehensive breast cancer risk prediction tools in health care for personalised prevention. Prev Med. 2022;159:107075.https:\/\/doi.org\/10.1016\/j.ypmed.2022.107075.","DOI":"10.1016\/j.ypmed.2022.107075"},{"key":"10237_CR5","doi-asserted-by":"publisher","unstructured":"Pashayan N, Antoniou AC, Ivanus U.  Personalized early detection and prevention of breast cancer: ENVISION consensus statement. Nat Rev Clin Oncol. 2020;17(11):687-705.  https:\/\/doi.org\/10.1038\/s41571-020-0388-9.","DOI":"10.1038\/s41571-020-0388-9"},{"key":"10237_CR6","doi-asserted-by":"publisher","unstructured":"Pashayan N, Morris S, Gilbert FJ, Pharoah PD.  Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model. JAMA Oncol. 2018;4(11):1504-1510.  https:\/\/doi.org\/10.1001\/jamaoncol.2018.1901.","DOI":"10.1001\/jamaoncol.2018.1901"},{"key":"10237_CR7","doi-asserted-by":"publisher","unstructured":"van Den Broek JJ, Schechter CB, van Ravesteyn NT.  Personalizing Breast Cancer Screening Based on Polygenic Risk and Family History. J Natl Cancer Inst. 2021;113(4):434-442.  https:\/\/doi.org\/10.1093\/jnci\/djaa127.","DOI":"10.1093\/jnci\/djaa127"},{"key":"10237_CR8","doi-asserted-by":"publisher","unstructured":"McCarthy AM, Guan Z, Welch M.  Performance of Breast Cancer Risk-Assessment Models in a Large Mammography Cohort. J Natl Cancer Inst. 2020;112(5):489-497.  https:\/\/doi.org\/10.1093\/jnci\/djz177.","DOI":"10.1093\/jnci\/djz177"},{"key":"10237_CR9","doi-asserted-by":"publisher","unstructured":"Louro J, Posso M, Hilton Boon M. A systematic review and quality assessment of individualised breast cancer risk prediction models. Br J Cancer. 2019;121(1):76-85.  https:\/\/doi.org\/10.1038\/s41416-019-0476-8.","DOI":"10.1038\/s41416-019-0476-8"},{"key":"10237_CR10","doi-asserted-by":"publisher","unstructured":"Gard CC, Tice JA, Miglioretti DL.  Extending the Breast Cancer Surveillance Consortium Model of Invasive Breast Cancer. J Clin Oncol. 2024;42(7):779-789.  https:\/\/doi.org\/10.1200\/JCO.22.02470.","DOI":"10.1200\/JCO.22.02470"},{"key":"10237_CR11","doi-asserted-by":"crossref","unstructured":"Tice JA, Cummings SR, Smith-Bindman R, Ichikawa L, Barlow WE, Kerlikowske K.  Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med. 2008;148(5):337-347.  148\/5\/337[pii].","DOI":"10.7326\/0003-4819-148-5-200803040-00004"},{"key":"10237_CR12","doi-asserted-by":"crossref","unstructured":"Gail MH, Brinton LA, Byar DP. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. JNCI: J Nat Cancer Instit. 1989;81(24):1879-86.","DOI":"10.1093\/jnci\/81.24.1879"},{"key":"10237_CR13","doi-asserted-by":"publisher","unstructured":"Costantino JP, Gail MH, Pee D.  Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst. 1999;91(18):1541-1548.  https:\/\/doi.org\/10.1093\/jnci\/91.18.1541.","DOI":"10.1093\/jnci\/91.18.1541"},{"key":"10237_CR14","doi-asserted-by":"publisher","unstructured":"Tyrer J, Duffy SW, Cuzick J.  A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004;23(7):1111-1130.  https:\/\/doi.org\/10.1002\/sim.1668.","DOI":"10.1002\/sim.1668"},{"key":"10237_CR15","doi-asserted-by":"publisher","unstructured":"U. S. Preventive Services Task Force, Owens DK, Davidson KW, et al. Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2019;322(9):857\u2013867.  https:\/\/doi.org\/10.1001\/jama.2019.11885.","DOI":"10.1001\/jama.2019.11885"},{"key":"10237_CR16","doi-asserted-by":"publisher","unstructured":"Van Ravesteyn NT, Miglioretti DL, Stout NK. Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years: a comparative modeling study of risk. Ann Int Med. 2012;156(9):609-17.https:\/\/doi.org\/10.7326\/0003-4819-156-9-201205010-00002.","DOI":"10.7326\/0003-4819-156-9-201205010-00002"},{"key":"10237_CR17","doi-asserted-by":"publisher","unstructured":"Trentham-Dietz A, Kerlikowske K, Stout NK.  Tailoring Breast Cancer Screening Intervals by Breast Density and Risk for Women Aged 50 Years or Older: Collaborative Modeling of Screening Outcomes. Ann Intern Med. 2016;165(10):700-712.  https:\/\/doi.org\/10.7326\/M16-0476.","DOI":"10.7326\/M16-0476"},{"key":"10237_CR18","doi-asserted-by":"publisher","unstructured":"Kerlikowske K, Sprague BL, Tosteson AN.  Strategies to Identify Women at High Risk of Advanced Breast Cancer During Routine Screening for Discussion of Supplemental Imaging. JAMA Intern Med. 2019;179(9):1230-1239.  https:\/\/doi.org\/10.1001\/jamainternmed.2019.1758.","DOI":"10.1001\/jamainternmed.2019.1758"},{"key":"10237_CR19","doi-asserted-by":"crossref","unstructured":"Kerlikowske K, Zhu W, Tosteson AN. Breast Cancer Surveillance Consortium*. Identifying women with dense breasts at high risk for interval cancer: a cohort study. Ann Int Med. 2015;162(10):673-81. https:\/\/doi.org\/10.7326\/M14-1465.","DOI":"10.7326\/M14-1465"},{"key":"10237_CR20","doi-asserted-by":"publisher","unstructured":"Sprague BL, Ichikawa L, Eavey J.  Performance of Supplemental US Screening in Women with Dense Breasts and Varying Breast Cancer Risk: Results from the Breast Cancer Surveillance Consortium. Radiology. 2024;312(2):e232380. https:\/\/doi.org\/10.1148\/radiol.232380.","DOI":"10.1148\/radiol.232380"},{"key":"10237_CR21","doi-asserted-by":"publisher","unstructured":"Howlader N, Cronin KA, Kurian AW, Andridge R.  Differences in Breast Cancer Survival by Molecular Subtypes in the United States. Cancer Epidemiol Biomarkers Prev. 2018;27(6):619-626.  https:\/\/doi.org\/10.1158\/1055-9965.EPI-17-0627.","DOI":"10.1158\/1055-9965.EPI-17-0627"},{"key":"10237_CR22","doi-asserted-by":"publisher","unstructured":"Kerlikowske K, Bissell MC, Sprague BL.  Advanced Breast Cancer Definitions by Staging System Examined in the Breast Cancer Surveillance Consortium. J Natl Cancer Inst. 2021;113(7): 909-916.  https:\/\/doi.org\/10.1093\/jnci\/djaa176.","DOI":"10.1093\/jnci\/djaa176"},{"key":"10237_CR23","doi-asserted-by":"publisher","unstructured":"Kerlikowske K, Chen S, Golmakani MK.  Cumulative Advanced Breast Cancer Risk Prediction Model Developed in a Screening Mammography Population. J Natl Cancer Inst. 2022;114(5):676-685.  https:\/\/doi.org\/10.1093\/jnci\/djac008.","DOI":"10.1093\/jnci\/djac008"},{"key":"10237_CR24","doi-asserted-by":"publisher","unstructured":"Lee CI, Abraham L, Miglioretti DL.  National Performance Benchmarks for Screening Digital Breast Tomosynthesis: Update from the Breast Cancer Surveillance Consortium. Radiology. 2023;307(4):e222499. https:\/\/doi.org\/10.1148\/radiol.222499.","DOI":"10.1148\/radiol.222499"},{"key":"10237_CR25","doi-asserted-by":"publisher","unstructured":"Lee CI, Bogart A, Germino JC.  Availability of Advanced Breast Imaging at Screening Facilities Serving Vulnerable Populations. J Med Screen. 2016;23(1):24-30.  https:\/\/doi.org\/10.1177\/0969141315591616.","DOI":"10.1177\/0969141315591616"},{"key":"10237_CR26","doi-asserted-by":"publisher","unstructured":"Lee CI, Zhu W, Onega T, et al. Comparative access to and use of digital breast tomosynthesis screening by Women's Race\/Ethnicity and Socioeconomic Status. JAMA Netw Open. 2021;4(2):e2037546.  https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.37546.","DOI":"10.1001\/jamanetworkopen.2020.37546"},{"key":"10237_CR27","unstructured":"American College of Radiology. ACR BI-RADS\u00ae - Mammography. 5th Edition. ACR BI-RADS Atlas: Breast Imaging Reporting and Data System. American College of Radiology; 2013."},{"key":"10237_CR28","doi-asserted-by":"publisher","unstructured":"Sprague BL, Kerlikowske K, Bowles EJ.  Trends in Clinical Breast Density Assessment From the Breast Cancer Surveillance Consortium. J Natl Cancer Inst. 2019;111(6):629-632.  https:\/\/doi.org\/10.1093\/jnci\/djy210.","DOI":"10.1093\/jnci\/djy210"},{"key":"10237_CR29","doi-asserted-by":"publisher","unstructured":"Tice JA, Miglioretti DL, Li CS, Vachon CM, Gard CC, Kerlikowske K.  Breast Density and Benign Breast Disease: Risk Assessment to Identify Women at High Risk of Breast Cancer. J Clin Oncol. 2015;33(28):3137-3143.  https:\/\/doi.org\/10.1200\/JCO.2015.60.8869.","DOI":"10.1200\/JCO.2015.60.8869"},{"key":"10237_CR30","doi-asserted-by":"publisher","unstructured":"U. S. Preventive Services Task Force, Nicholson WK, Silverstein M, et al. Screening for Breast Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2024. https:\/\/doi.org\/10.1001\/jama.2024.5534.","DOI":"10.1001\/jama.2024.5534"},{"key":"10237_CR31","doi-asserted-by":"publisher","unstructured":"Li NHY, Li CI. Incidence Rate Trends of Breast Cancer Overall and by Molecular Subtype by Race and Ethnicity and Age. JAMA Netw Open. 2025;8(1):e2456142.  https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.56142.","DOI":"10.1001\/jamanetworkopen.2024.56142"},{"key":"10237_CR32","doi-asserted-by":"publisher","unstructured":"Smith RA, Andrews  KS, Brooks D.  Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2017;67(2):100-121.  https:\/\/doi.org\/10.3322\/caac.21392.","DOI":"10.3322\/caac.21392"},{"key":"10237_CR33","doi-asserted-by":"publisher","unstructured":"Expert Panel on Breast Imaging, Niell BL, Jochelson MS, et al. ACR Appropriateness Criteria(R) Female Breast Cancer Screening: 2023 Update. J Am Coll Radiol. 2024;21(6S):S126-S143.  https:\/\/doi.org\/10.1016\/j.jacr.2024.02.019.","DOI":"10.1016\/j.jacr.2024.02.019"},{"key":"10237_CR34","doi-asserted-by":"publisher","unstructured":"Expert Panel on Breast Imaging, Weinstein SP, Slanetz PJ, et al. ACR Appropriateness Criteria(R) supplemental breast cancer screening based on breast density. J Am Coll Radiol. 2021;18(11S):S456-S473.  https:\/\/doi.org\/10.1016\/j.jacr.2021.09.002.","DOI":"10.1016\/j.jacr.2021.09.002"},{"key":"10237_CR35","doi-asserted-by":"publisher","unstructured":"Autier P, H\u00e9ry C, Haukka J, Boniol M, Byrnes G.  Advanced breast cancer and breast cancer mortality in randomized controlled trials on mammography screening. J Clin Oncol. 2009;27(35):5919-5923.  https:\/\/doi.org\/10.1200\/JCO.2009.22.7041.","DOI":"10.1200\/JCO.2009.22.7041"},{"key":"10237_CR36","doi-asserted-by":"publisher","unstructured":"Hu P, Steingrimsson JA, Cole E.  Design considerations and challenges in the CHinA National CancEr Screening (CHANCES) trial and Tomosynthesis Mammographic Imaging Screening Trial (TMIST). J Natl Cancer Inst Monogr. 2025;68:42-48.  https:\/\/doi.org\/10.1093\/jncimonographs\/lgae049.","DOI":"10.1093\/jncimonographs\/lgae049"},{"key":"10237_CR37","doi-asserted-by":"publisher","unstructured":"Feng X, Zahed H, Onwuka J.  Cancer Stage Compared With Mortality as End Points in Randomized Clinical Trials of Cancer Screening: A Systematic Review and Meta-Analysis. JAMA. 2024;331(22):1910-1917.  https:\/\/doi.org\/10.1001\/jama.2024.5814.","DOI":"10.1001\/jama.2024.5814"},{"key":"10237_CR38","doi-asserted-by":"publisher","unstructured":"Miglioretti DL, Zhu W, Kerlikowske K. Breast cancer surveillance consortium. breast tumor prognostic characteristics and biennial vs annual mammography, age, and menopausal status. JAMA Oncol. 2015;1(8):1069-77. https:\/\/doi.org\/10.1001\/jamaoncol.2015.3084.","DOI":"10.1001\/jamaoncol.2015.3084"},{"key":"10237_CR39","doi-asserted-by":"publisher","unstructured":"Kerlikowske K, Zhu W, Su YR. Supplemental magnetic resonance imaging plus mammography compared with magnetic resonance imaging or mammography by extent of breast density. J Natl Cancer Inst. 2024;116(2):249-257.  https:\/\/doi.org\/10.1093\/jnci\/djad201.","DOI":"10.1093\/jnci\/djad201"},{"key":"10237_CR40","doi-asserted-by":"publisher","unstructured":"Kerlikowske K, Su YR, Sprague BL. Association of screening with digital breast tomosynthesis vs digital mammography with risk of interval invasive and advanced breast cancer. Jama. 2022;327(22):2220-30.  https:\/\/doi.org\/10.1001\/jama.2022.7672.","DOI":"10.1001\/jama.2022.7672"},{"key":"10237_CR41","doi-asserted-by":"publisher","unstructured":"Visvanathan K, Fabian CJ, Bantug E.  Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2019;37(33):3152-3165.  https:\/\/doi.org\/10.1200\/JCO.19.01472.","DOI":"10.1200\/JCO.19.01472"},{"key":"10237_CR42","doi-asserted-by":"publisher","unstructured":"Bevers TB, Ward JH, Arun BK, et al. Breast Cancer Risk Reduction, Version 2.2015. J Natl Compr Canc Netw. 2015;13(7):880\u2013915.  https:\/\/doi.org\/10.6004\/jnccn.2015.0105.","DOI":"10.6004\/jnccn.2015.0105"},{"key":"10237_CR43","doi-asserted-by":"publisher","unstructured":"Farkas A, Vanderberg R, Merriam S, DiNardo D.   Breast Cancer Chemoprevention: A Practical Guide for the Primary Care Provider. J Womens Health (Larchmt). 2020;29(1):46-56.  https:\/\/doi.org\/10.1089\/jwh.2018.7643.","DOI":"10.1089\/jwh.2018.7643"},{"key":"10237_CR44","doi-asserted-by":"publisher","unstructured":"Chlebowski RT, Aragaki AK, Pan K. Breast Cancer Prevention: Time for Change. JCO Oncol Pract. 2021;17(12):709-716  https:\/\/doi.org\/10.1200\/OP.21.00343.","DOI":"10.1200\/OP.21.00343"},{"key":"10237_CR45","doi-asserted-by":"publisher","unstructured":"Tice JA, Bissell MC, Miglioretti DL.  Validation of the breast cancer surveillance consortium model of breast cancer risk. Breast Cancer Res Treat. 2019;175(2)5:19-523.  https:\/\/doi.org\/10.1007\/s10549-019-05167-2.","DOI":"10.1007\/s10549-019-05167-2"},{"key":"10237_CR46","doi-asserted-by":"publisher","unstructured":"Vachon CM, Pankratz VS, Scott CG, et al. The contributions of breast density and common genetic variation to breast cancer risk. J Natl Cancer Inst.  2015;107(5):dju397. https:\/\/doi.org\/10.1093\/jnci\/dju397.","DOI":"10.1093\/jnci\/dju397"},{"key":"10237_CR47","doi-asserted-by":"publisher","unstructured":"Kim G, Bahl M.  Assessing Risk of Breast Cancer: A Review of Risk Prediction Models J Breast Imaging. 2021;3(2):144-155.  https:\/\/doi.org\/10.1093\/jbi\/wbab001.","DOI":"10.1093\/jbi\/wbab001"},{"key":"10237_CR48","doi-asserted-by":"publisher","unstructured":"McCarthy AM, Liu Y, Ehsan S, et al. Validation of Breast Cancer Risk Models by Race\/Ethnicity, Family History and Molecular Subtypes. Cancers (Basel). 2021;14(1). https:\/\/doi.org\/10.3390\/cancers14010045.","DOI":"10.3390\/cancers14010045"},{"key":"10237_CR49","doi-asserted-by":"publisher","unstructured":"Coopey SB, Acar A, Griffin M, Cintolo-Gonzalez J, Semine A, Hughes KS. The impact of patient age on breast cancer risk prediction models. Breast J. 2018;24(4):592-598.https:\/\/doi.org\/10.1111\/tbj.12976.","DOI":"10.1111\/tbj.12976"},{"key":"10237_CR50","doi-asserted-by":"publisher","unstructured":"Hollingsworth AB, Li FY, Morse AN. Lifetime risks for breast cancer are age-discriminatory when used for high-risk screening with MRI. Cancer epidemiology. Jun 2022;78:102122. https:\/\/doi.org\/10.1016\/j.canep.2022.102122.","DOI":"10.1016\/j.canep.2022.102122"},{"key":"10237_CR51","unstructured":"United States Department of Commerce, U.S. Census Bureau, Population Division. Single-race Population Estimates, United States, 2020\u20132022, on CDC WONDER Online Database.    http:\/\/wonder.cdc.gov\/single-race-single-year-v2022.html . Accessed 6 Dec 2024."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-026-10237-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-026-10237-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-026-10237-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:14:51Z","timestamp":1789132491000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-026-10237-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":51,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10237"],"URL":"https:\/\/doi.org\/10.1007\/s11606-026-10237-5","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]},"assertion":[{"value":"23 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Each BCSC registry and the Statistical Coordinating Center (SCC) received institutional review board approval for all study procedures, including active or passive consenting processes or a waiver of consent. All procedures were compliant with the Health Insurance Portability and Accountability Act.","order":1,"name":"Ethics","label":"Human Ethics and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. C. Lee reports textbook royalties from McGraw Hill, Inc., Oxford University Press, and UpToDate, Inc.; research consulting fees from DeepHealth\/RadNet; and personal fees for journal editorial board work from the American College of Radiology, all outside the submitted work. Dr. Miglioretti received textbook royalties from Elsevier. Dr. Kerlikowske is an unpaid consultant with Grail Inc. for the STRIVE study. No other conflict of interest disclosures were reported.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}